Skip to content

Percent Weight Change in the Medical Supplement Group of Early Breast Cancer

Effects of Body Weight Change in the Medical Supplement Group in Patients with Early Breast Cancer During Chemotherapy: a Randomized, Controlled Trial

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06311357
Enrollment
40
Registered
2024-03-15
Start date
2023-07-12
Completion date
2024-12-30
Last updated
2024-12-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Early Stage Breast Cancer

Keywords

Medical supplement, Weight change in early breast cancer treatment

Brief summary

The goal of this RCT is to compare percent weight change in early breast cancer who takes medical supplement or not, during treatment with chemotherapy (standard AC regimen). The main question is • the change of weight (%) before and after complete treatment of breast cancer therapy. Participants will be randomized into 2 group * intervention group - receive medical supplement daily during chemotherapy treatment. * control group - Nutritional advise during chemotherapy treatment.

Detailed description

1. The rational is to prove the hypothesis is that, the effect of medical supplement with nutritional advise can prevent the reduction of body weight, malnutrition and treatment complication, which eventually to improve of the quality of life. 2. Primary endpoint of the study is to compare the effect of medical supplement on percent weight change in early breast cancer who received chemotherapy in Rajavithi hospital. Secondary endpoints are nutritional status (PG-SGA), quality of life. 3. Sample size formula based on Bernard R. Fundamentals of biostatistics. 5th ed. Duxbery: Thomson learning; 2000. Enrollment of 40 patients. 4. Randomization into 2 groups. Intervention arm : receive medical supplement daily (1 drink = 6 scoops in 250 ml water, 2 drinks/day) with nutritional advise. Control arm : nutritional advise only. Duration of treatment is 12 weeks 5. Enrollment and data monitoring is assessed by the staffs of oncology department in Rajavithi hospital and the data will be recorded in computer based information system. 6. Data assessment on week 0,6,12 during chemotherapy treatment. 7. Data analyzed by descriptive statistics to characterize patients at entry. We did the efficacy analyses with intention to treat population 8. We did analyses with R version 3.3.0.

Interventions

DIETARY_SUPPLEMENTEnsure

Ensure 6 scoops dietary supplement powder in 250 ml of water, 2 drinks per days for 12 weeks.

Sponsors

Department of Medical Services Ministry of Public Health of Thailand
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Histopathological confirmed diagnosis of breast cancer * Breast cancer stage I-III * Recieve adjuvant or neoadjuvant doxorubicin and cyclophosphamide at Rajavithi hospital * LVEF \>= 60% - ECOG score 0-1

Exclusion criteria

* No indication for chemotherapy * Contraindication for chemotherapy * Breast cancer stage IV * Diabetic mellitus who requires insulin injection * BMI \>= 30 kg/m2 or \<= 16 kg/m2 * Previously known other malignancies * Second primary cancer * Previously received chemotherapy or radiotherapy * Severe malnutrition with administration of TPN is indicated * Pregnancy or lactation * CKD stage 4-5

Design outcomes

Primary

MeasureTime frameDescription
Percent weight change12 weeksThe change of body weight (%) before and after chemotherapy treatment

Secondary

MeasureTime frameDescription
EORTC QLQ-BR2312 weeksThe change of Global Quality of life before and after chemotherapy treatment score
EORTC QLQ-C3012 weeksThe change of Global Quality of life before and after chemotherapy treatment score
Patient interpretation of the Patient-Generated Subjective Global Assessment12 weeksPG-SGA

Countries

Thailand

Contacts

Primary ContactMeitinarth Juntong
juntong.mei@gmail.com+66654415447

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026